Nautilus Biotechnology is trading at $2.57, down 5.17%, during the October 22, 2026 session amid broad market weakness.
- No clear company-specific announcement explaining the decline surfaced.
- The Nasdaq fell 2.27% and the S&P 500 fell 1.26%; AI-spending concerns and rising oil prices may add pressure, though no direct link was reported.
- The company’s latest release schedules third-quarter results for October 27, 2026; the upcoming report does not explain today’s move.